glp 1 drugs in development What is the pipeline for future medications for obesity? Current Insights, Advantages and Challenges

5Chemotherapy drugs cisplatin (most common) carboplatin (less frequent) They cause renal tubular damage and persistent magnesium loss, sometimes lasting months after therapy

This question concerns many patients prescribed glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda) for type 2 diabetes or weight management

This makes them an excellent option for those dealing with age-related metabolic slowdown

It is projected to reach USD 1,062.90 billion by 2035

While these medications create a powerful sensation of reduced stomach capacity, the reality involves functional rather than structural changes

J Hepatol (2011) 54:121423